CD18抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CD18 mouse mAb against HL-60 (1) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD18 mouse mAb (green) and negative control (red).    

  
  

CD18. a key component of the β₂ integrin family, is a transmembrane protein that pairs with distinct α subunits (CD11a-d) to form leukocyte-specific adhesion molecules, including LFA-1 (CD11a/CD18), Mac-1 (CD11b/CD18), and others. These β₂ integrins are critical for immune cell functions such as leukocyte migration, phagocytosis, and immunological synapse formation. CD18 antibodies target this subunit, disrupting integrin-mediated interactions with ligands like ICAM-1. which play roles in inflammation and immune responses.

Research on CD18 antibodies stems from their relevance in leukocyte adhesion deficiency type I (LAD-I), a rare immunodeficiency caused by CD18 mutations, characterized by recurrent infections and impaired wound healing. In therapeutic contexts, CD18-blocking antibodies have been explored to mitigate pathological inflammation in conditions like ischemia-reperfusion injury, autoimmune diseases, or transplant rejection. Conversely, agonist antibodies may enhance leukocyte adhesion in immunodeficiency settings.

While early preclinical studies demonstrated potential, clinical translation has faced challenges due to complex integrin signaling and off-target effects. Nonetheless, CD18 remains a biomarker and research tool for studying leukocyte behavior, immune dysregulation, and targeted immunomodulation. Ongoing work focuses on optimizing antibody specificity and understanding context-dependent CD18 roles in health and disease.